Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

ORTHO PRESIDENT WILSON AND MCNEIL CONSUMER CHAIRMAN COLLINS MOVE UP to join a new triumvirate of vice-chairmen at Johnson & Johnson in management changes announced May 2. Robert Wilson, 44, is the youngest of the new senior management group. He has been in charge of Ortho since he was appointed president in 1979 when he was 39 years old. In 1983, he was appointed to the Executive Cmte. and expanded his executive responsibilities beyond Ortho Pharmaceuticals to McNeil Pharmaceuticals and the Cilag businesses overseas. David Collins, 50, has been the Executive Cmte. member in charge of J&J's consumer products business worldwide. Collins has the broadest range of management experience among the new triumvirate of vice-chairmen. The third member of the triumvirate is Robert Campbell, 51, a 26-year veteran of J&J who currently serves on the board of directors and the Executive Cmte. Campbell's background has been primarily in financial management. For the last two years, he has had line management responsibility in the professional health care products sector. Campbell will be chief executive for professional health care products worldwide and companies in Mexico, Central and South America and the Caribbean. The three-person group of chief executive officers -- each with responsibility for one of the major J&J business segments -- mirrors a similar approach in use at Bristol-Myers for the last three years. J&J Chairman James Burke and President David Clare said: "The creation of these new positions is designed to better coordinate the company's diverse businesses and to enhance faster decision-making." The two top corporate officers added that "the new structure is appropriate for the diversified health care company because it is expanding both geographically and in product technology." A lawyer by training, Collins has been J&J's general counsel as well as head of the McNeil Rx business and a manager of South American operations before taking charge of consumer products worldwide. Collins took over the consumer products responsibilities just two weeks prior to the Tylenol poisonings and played a major role in J&J's response to that crisis. Collins has also been active in broader industry issues. For example, he was an active participant in the establishment of a trade assn. group for the medical device industry (HIMA) and he recently was chosen to head a special Proprietary Assn. cmte. to keep track of the impact of the internatl. marketing code discussions on the OTC drug industry. Wilson was recently chosen to represent J&J on the PMA board. Under Wilson's direction, Ortho has made gains in its position in the U.S. market. The oral contraceptive Ortho-Novum, for example, moved up to the Number 4 product on the list of U.S. retail drugs in terms of dollar volume sales to pharmacies in 1983, according to the Pharmaceutical Data Services market survey. The product was Number 11 among the Top 20 selling retail products the year before. On the strength of the oral contraceptive performance, Ortho moved up to the Number 12 retail marketing company in the U.S. The firm had U.S. sales in 1984 of about $350-$360 mil.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts